RecruitingPhase 2NCT06899165

Psilocybin-Assisted Therapy for Intergenerational Trauma

Processing Intergenerational Trauma With Psilocybin-Assisted Therapy


Sponsor

Rachel Yehuda

Enrollment

100 participants

Start Date

Aug 28, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing psilocybin-assisted therapy for people who are the children of genocide survivors and who are currently living with depression or anxiety. Research suggests that trauma can be passed down across generations — a phenomenon called intergenerational trauma — and that it can affect mental health in the children of those who were directly harmed. This study aims to find out whether psilocybin, given in a supportive therapeutic setting, can help heal this kind of deep-rooted psychological distress. **You may be eligible if...** - You are at least 18 years old - At least one of your biological parents directly survived or escaped a genocide - You have been diagnosed with a depressive or anxiety disorder - You are fluent in English and able to swallow pills - You are willing to use contraception and commit to all study visits and procedures **You may NOT be eligible if...** - You yourself directly survived or escaped a genocide - You have a history of psychosis, schizophrenia, or bipolar disorder - You have a serious heart, neurological, or other medical condition that could make psilocybin unsafe - You are pregnant or breastfeeding - You are currently taking medications that interact with psilocybin (such as lithium or MAOIs) - You are enrolled in another interventional clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPsilocybin

Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists

BEHAVIORALIntegration sessions

weekly integration sessions (therapy) for 6 weeks


Locations(1)

The Parsons Research Center for Psychedelic Healing

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06899165


Related Trials